Fig. 1From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trialTTP and duration of treatment in patients with best response of SD to romidepsin. PTCL subtypes and response by exploratory PET endpoint are shown on Y axis. Vertical line indicates 90 days of treatment; asterisk indicates patients that discontinued due to adverse event; and dagger sign indicates patients that discontinued due to patient decision. E-type TCL enteropathy-type T cell lymphoma, P-like TCL subcutaneous panniculitis-like T cell lymphomaBack to article page